CG Oncology, Inc. (CGON) AI Stock Analysis

• Market Cap: $2.02B
• Dividend Yield: N/A
• Average Volume (3M): 1.20M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.99
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 113
• Sector: General
• Sector Strength: N/A
• Industry: Biotechnology
• EPS (TTM): -0.45
• Shares Outstanding: 76,225,310
• 10 Day Avg. Volume: 799,452
• 30 Day Avg. Volume: 1,197,562
• PEG Ratio: -0.39
• Price to Book (P/B): 19.79
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -83.07
• Enterprise Value/Market Cap: 1.19
• Enterprise Value/Revenue: 767.15
• Enterprise Value/Gross Profit: 3.67K
• Enterprise Value/Ebitda: -5.64
• 1Y Price Target: $59.88
• Price Target Upside: 125.96% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 9

• Rating: 55 Neutral
• Price Target: $27.00 ▲(1.89%Upside)

CG Oncology's overall score is buoyed by promising trial results, indicating potential future success in the biotech field. However, financial challenges and current lack of revenue weigh down the score. The technical analysis shows moderate strength, and valuation metrics are weak due to ongoing losses.

Positive Factors

Clinical Data

Creto's clinical positioning in BCG-unresponsive, high-risk NMIBC was strengthened by the disappointing TAR-200 data.

Financial Performance

The current valuation is significantly disconnected from the underlying fundamentals, suggesting potential for growth.

Market Opportunity

The analyst remains positive on the market opportunity and label expansion potential for creto.

Negative Factors

Treatment Side Effects

Dr. Ghodoussipour was a bit hesitant on the higher frequency of grade 3+ TRAEs and discontinuations with TAR-200.

CG Oncology, Inc. Business Overview & Revenue Model

Company Description

CG Oncology, Inc. (CGON) is a biotechnology company focused on the development and commercialization of innovative immuno-oncology therapies for patients with cancer. The company's primary product candidates are based on oncolytic immunotherapy, which utilizes genetically modified viruses to selectively target and destroy cancer cells while stimulating an immune response against tumors. CG Oncology's lead product candidate, CG0070, is in advanced clinical trials for the treatment of bladder cancer and other solid tumors.

How the Company Makes Money

CG Oncology makes money primarily through the development and potential commercialization of its proprietary cancer therapies. Revenue streams include partnerships with pharmaceutical companies for co-development, out-licensing of its technology for specific indications or regions, and potential future sales of its approved therapies. The company may also receive milestone payments and royalties from partners, contingent on the successful development and commercialization of its product candidates. Additionally, CG Oncology may benefit from governmental or institutional grants to support its research and development activities.

CG Oncology, Inc. Financial Statement Overview

Summary

CG Oncology, Inc. is facing financial challenges typical of early-stage biotechnology firms, with no current revenue and significant operating losses. The strong equity position and cash reserves provide some stability, but the reliance on external funding indicates potential risks if capital markets shift. The company’s focus should be on achieving revenue growth and improving operational efficiencies to sustain long-term viability.

Income Statement

CG Oncology, Inc. reported zero revenue in the latest year, indicating challenges in generating income. The company has experienced consistent losses with deteriorating EBIT and EBITDA margins, reflecting operational inefficiencies and potential barriers in monetizing its biotechnology developments.

Balance Sheet

The company's strong equity base relative to total assets, demonstrated by a high equity ratio, provides a solid financial foundation. However, the minimal debt levels and high cash reserves suggest limited leverage but also an underutilization of potential financing for growth.

Cash Flow

The negative free cash flow and significant negative operating cash flow highlight ongoing cash burn issues. Despite substantial financing inflows, the company is heavily reliant on external funding for operations, which could pose risks if such funding diminishes.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement		Total Revenue
662.00K	1.14M	204.00K	191.00K	10.36M
	Gross Profit
655.00K	1.14M	204.00K	176.00K	10.35M
	EBIT
-134.40M	-114.67M	-55.45M	-35.25M	-12.61M
	EBITDA
-134.36M	-114.63M	-55.43M	-35.23M	-12.38M
	Net Income Common Stockholders
-105.56M	-88.04M	-48.61M	-35.44M	-12.84M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
688.43M	742.00M	187.67M	143.48M	53.61M
	Total Assets
728.18M	754.80M	199.30M	147.75M	58.69M
	Total Debt
1.04M	238.00K	461.00K	16.30M	15.48M
	Net Debt
-40.44M	-256.83M	-7.80M	-71.85M	-38.13M
	Total Liabilities
23.42M	21.42M	14.51M	22.57M	18.44M
	Stockholders Equity
704.76M	733.38M	184.79M	125.18M	40.25M
Cash Flow		Free Cash Flow
-82.22M	-78.95M	-45.68M	-29.82M	-13.75M
	Operating Cash Flow
-81.98M	-78.71M	-45.68M	-29.80M	-13.65M
	Investing Cash Flow
-180.09M	-300.76M	-121.19M	-55.35M	-97.00K
	Financing Cash Flow
226.07M	628.28M	87.00M	119.69M	15.45M

CG Oncology, Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 26.50
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CGON, the sentiment is Negative. The current price of 26.5 is above the 20-day moving average (MA) of 26.17, above the 50-day MA of 23.81, and below the 200-day MA of 30.00, indicating a neutral trend. The MACD of 0.53 indicates Positive momentum. The RSI at 50.37 is Neutral, neither overbought nor oversold. The STOCH value of 32.04 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CGON.

CG Oncology, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	58 Neutral	$4.96B	18.48	-17.00%	7.20%	13.61%	-24.47%
CGON	55 Neutral	$2.02B	―	-16.57%	―	―	―
GUTS	55 Neutral	$106.28M	―	-196.81%	―	―	―
MGX	51 Neutral	$54.20M	―	-31.93%	―	-4.22%	18.67%
ANRO	42 Neutral	$66.33M	―	-38.04%	―	―	―
FBLG	38 Underperform	$33.38M	―	-559.73%	―	―	―
KYTX	36 Underperform	$143.05M	―	-49.72%	―	―	―

CG Oncology, Inc. Corporate Events

CG Oncology Holds 2025 Annual Stockholders Meeting

On June 5, 2025, CG Oncology, Inc. held its 2025 Annual Meeting of Stockholders where key decisions were made regarding the company’s leadership and auditing practices. The stockholders elected three Class I directors to serve until the 2028 Annual Meeting and ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

The most recent analyst rating on (CGON) stock is a Buy with a $86.00 price target. To see the full list of analyst forecasts on CG Oncology, Inc. stock, see the CGON Stock Forecast page.

CG Oncology Announces Promising Phase 3 Trial Results

On April 26, 2025, CG Oncology announced promising results from its Phase 3 BOND-003 clinical trial at the American Urological Association Annual Meeting. The trial data showed a 75.5% complete response rate at any time for patients with high-risk BCG-unresponsive non-muscle invasive bladder cancer treated with cretostimogene grenadenorepvec. The 24-month complete response rate was 42.3%, with a median duration of response of 28 months. Additionally, 97.3% of patients remained free from progression to muscle-invasive disease, and the treatment was well-tolerated with no severe adverse events reported. Cohort P also showed a high-grade recurrence-free survival rate of 90.5% at 3 and 9 months. These results position cretostimogene as a potential breakthrough therapy for bladder cancer, offering distinct advantages over existing treatments.

CG Oncology’s Promising Phase 3 Trial Results Revealed

On March 24, 2025, CG Oncology announced updated data from the BOND-003 Phase 3 clinical trial for cretostimogene, an investigational oncolytic immunotherapy for high-risk BCG-unresponsive non-muscle invasive bladder cancer. The data revealed a 75.5% complete response rate among patients, with a median duration of response exceeding 28 months and no Grade 3 or higher treatment-related adverse events. These findings, presented at the European Association of Urology Congress, highlight cretostimogene’s potential as a breakthrough bladder cancer treatment, pending FDA approval.